<DOC>
	<DOC>NCT01860508</DOC>
	<brief_summary>PFS</brief_summary>
	<brief_title>A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>.≥65 years or PS 2 Patients who were diagnosed by the histologic, cytologic diagnosis of IV nonsmall cell lung cancer Patients received no chemical therapy or only received targeted therapy,and there is evidence show the patent is PD Presence of at least one index lesion measurable by CT scan or MRI leucocyte ≥ 3.5×109/L neutrophil ≥ 1.5×109/L platelet ≥ 80×109/L Hemoglobin ≥ 9g/L ALT and AST ≤ 2.5×ULN ,Tbil≤ 1.5×ULN BUN≤ 1.5×ULN Signed written informed consent squamous carcinoma or small cell lung cancer Patients were allergic to pemetrexed Patients received chemotherapy before Uncontrolled acute infection .Uncontrolled pleural effusion Severe symptomatic heart disease Severe infection or metabolic disfunction Patients with other malignant tumor Uncontrolled brain metastases Patients have accepted other clinical trials Female patients during their pregnant and lactation period, or patients without contraception Mental disorientation of disorder Glucocorticoids taboo</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Progression free Survival</keyword>
</DOC>